Business Description
Iterum Therapeutics PLC
NAICS : 325412
SIC : 2836
ISIN : IE000TTOOBX0
Description
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.26 | |||||
| Equity-to-Asset | -0.24 | |||||
| Debt-to-Equity | -2.96 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 50.9 | |||||
| 3-Year EPS without NRI Growth Rate | 51.5 | |||||
| 3-Year FCF Growth Rate | 55.3 | |||||
| 3-Year Book Growth Rate | 68.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.63 | |||||
| 9-Day RSI | 61.68 | |||||
| 14-Day RSI | 56.96 | |||||
| 6-1 Month Momentum % | 132.84 | |||||
| 12-1 Month Momentum % | 56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.89 | |||||
| Quick Ratio | 1.89 | |||||
| Cash Ratio | 1.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -60 | |||||
| Shareholder Yield % | -0.34 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -375.35 | |||||
| ROA % | -79.29 | |||||
| ROIC % | -1101.69 | |||||
| ROC (Joel Greenblatt) % | -58596.77 | |||||
| ROCE % | -98.53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.62 | |||||
| EV-to-Forward-EBIT | -0.45 | |||||
| EV-to-EBITDA | -0.65 | |||||
| EV-to-FCF | -0.57 | |||||
| Earnings Yield (Greenblatt) % | -161.29 | |||||
| FCF Yield % | -143.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ITRM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Iterum Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.97 | ||
| Beta | 3.35 | ||
| Volatility % | 198.56 | ||
| 14-Day RSI | 56.96 | ||
| 14-Day ATR ($) | 0.117568 | ||
| 20-Day SMA ($) | 1.597 | ||
| 12-1 Month Momentum % | 56 | ||
| 52-Week Range ($) | 0.622 - 2.5 | ||
| Shares Outstanding (Mil) | 16.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Iterum Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Iterum Therapeutics PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Iterum Therapeutics PLC Frequently Asked Questions
What is Iterum Therapeutics PLC(ITRM)'s stock price today?
The current price of ITRM is $1.67. The 52 week high of ITRM is $2.50 and 52 week low is $0.62.
When is next earnings date of Iterum Therapeutics PLC(ITRM)?
The next earnings date of Iterum Therapeutics PLC(ITRM) is 2024-05-10 Est..
Does Iterum Therapeutics PLC(ITRM) pay dividends? If so, how much?
Iterum Therapeutics PLC(ITRM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers